AlzeCure Pharma (Sweden) Performance
| ALZCUR Stock | SEK 1.19 0.16 15.53% |
The firm shows a Beta (market volatility) of 0.94, which signifies possible diversification benefits within a given portfolio. AlzeCure Pharma returns are very sensitive to returns on the market. As the market goes up or down, AlzeCure Pharma is expected to follow. At this point, AlzeCure Pharma has a negative expected return of -0.69%. Please make sure to confirm AlzeCure Pharma's value at risk, daily balance of power, as well as the relationship between the Daily Balance Of Power and price action indicator , to decide if AlzeCure Pharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days AlzeCure Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 112.4 M | |
| Total Cashflows From Investing Activities | -54 K |
AlzeCure |
AlzeCure Pharma Relative Risk vs. Return Landscape
If you would invest 199.00 in AlzeCure Pharma on September 1, 2024 and sell it today you would lose (80.00) from holding AlzeCure Pharma or give up 40.2% of portfolio value over 90 days. AlzeCure Pharma is generating negative expected returns and assumes 4.2466% volatility on return distribution over the 90 days horizon. Simply put, 37% of stocks are less volatile than AlzeCure, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
AlzeCure Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AlzeCure Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as AlzeCure Pharma, and traders can use it to determine the average amount a AlzeCure Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1618
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ALZCUR |
Estimated Market Risk
| 4.25 actual daily | 37 63% of assets are more volatile |
Expected Return
| -0.69 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.16 actual daily | 0 Most of other assets perform better |
Based on monthly moving average AlzeCure Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AlzeCure Pharma by adding AlzeCure Pharma to a well-diversified portfolio.
AlzeCure Pharma Fundamentals Growth
AlzeCure Stock prices reflect investors' perceptions of the future prospects and financial health of AlzeCure Pharma, and AlzeCure Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AlzeCure Stock performance.
| Return On Equity | -1.55 | |||
| Return On Asset | -0.78 | |||
| Current Valuation | 173.51 M | |||
| Shares Outstanding | 59.19 M | |||
| Price To Book | 6.62 X | |||
| EBITDA | (77.2 M) | |||
| Cash And Equivalents | 222.05 M | |||
| Cash Per Share | 5.88 X | |||
| Book Value Per Share | 0.63 X | |||
| Cash Flow From Operations | (70.64 M) | |||
| Earnings Per Share | (1.78) X | |||
| Total Asset | 45.65 M | |||
About AlzeCure Pharma Performance
By analyzing AlzeCure Pharma's fundamental ratios, stakeholders can gain valuable insights into AlzeCure Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if AlzeCure Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if AlzeCure Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
AlzeCure Pharma AB develops therapies for the treatment of Alzheimer s disease and related neurodegenerative disorders. The company was founded in 2012 and is based in Huddinge, Sweden. AlzeCure Pharma is traded on Stockholm Stock Exchange in Sweden.Things to note about AlzeCure Pharma performance evaluation
Checking the ongoing alerts about AlzeCure Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AlzeCure Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AlzeCure Pharma generated a negative expected return over the last 90 days | |
| AlzeCure Pharma may become a speculative penny stock | |
| AlzeCure Pharma has high historical volatility and very poor performance | |
| AlzeCure Pharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (77.78 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| AlzeCure Pharma has accumulated about 222.05 M in cash with (70.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.88, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 41.0% of the company shares are held by company insiders |
- Analyzing AlzeCure Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AlzeCure Pharma's stock is overvalued or undervalued compared to its peers.
- Examining AlzeCure Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AlzeCure Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of AlzeCure Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AlzeCure Pharma's stock. These opinions can provide insight into AlzeCure Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for AlzeCure Stock analysis
When running AlzeCure Pharma's price analysis, check to measure AlzeCure Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AlzeCure Pharma is operating at the current time. Most of AlzeCure Pharma's value examination focuses on studying past and present price action to predict the probability of AlzeCure Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AlzeCure Pharma's price. Additionally, you may evaluate how the addition of AlzeCure Pharma to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |